Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE)

Abstract

The adhesion molecule L-selectin (CD62L) mediates lymphocyte recirculation and leucocyte roiling on vascular endothelium at sites of inflammation. Serum levels of soluble L-selectin (SL-selectin) were measured in patients with SLE in order to relate these levels to clinical activity and immunological parameters. An ELISA was used to detect the soluble form of human L-selectin (CD62L) in 42 patients with SLE and in 33 healthy individuals. The mean ± s.e.m. values of SL-selectin were 1285 ± 121 ng/ml for patients with SLE and 986 ± 180 ng/ml for healthy blood donors, but there was no significant difference. When patients with active SLE were analysed, higher levels of circulating SL-selectin were found when compared with patients without activity (1497 ± 167 ng/ml versus 941 ± 150 ng/ml; P = 0.028). We found a significant correlation between the levels of SL- selectin and of dsDNA antibodies (r = 0.36, P = 0.044) and between levels of SL-selectin and SLE Disease Activity Index (SLEDAI) score (r = 0.42, P = 0.003). Patients with active SLE studied cross-sectionally showed significant elevations of SL-selectin (CD62L) compared with controls. Thus, the levels of this soluble adhesion molecule correlated with active disease and levels of anti-dsDNA antibodies.